title: n-3 Polyunsaturated Fatty Acid Supplementation Has No Effect on Postprandial Triglyceride-Rich Lipoprotein Kinetics in Men with Type 2 Diabetes.
abstract: Dietary n-3 polyunsaturated fatty acids (PUFAs) have been proposed to modulate plasma lipids, lipoprotein metabolism, and inflammatory state and to reduce triglyceride (TG) concentrations. The present double-blind, randomized, placebo-controlled, crossover study investigated the effects of n-3 PUFA supplementation at 3 g/d for 8 weeks on the intravascular kinetics of intestinally derived apolipoprotein (apo) B-48-containing lipoproteins in 10 men with type 2 diabetes. In vivo kinetics of the TG-rich lipoprotein (TRL) apoB-48 and VLDL apoB-100 were assessed using a primed-constant infusion of L-[5,5,5-D3] leucine for 12 hours in a fed state. Compared with the placebo, n-3 PUFA supplementation significantly reduced fasting TG concentrations by -9.7% (P = 0.05) but also significantly increased plasma levels of cholesterol (C) (+6.0%, P = 0.05), LDL-C (+12.2%, P = 0.04), and HDL-C (+8.4, P = 0.007). n-3 PUFA supplementation had no significant impact on postprandial TRL apoB-48 and VLDL apoB-100 levels or on the production or catabolic rates of these lipoproteins. These data indicate that 8-week supplementation with n-3 PUFAs in men with type 2 diabetes has no beneficial effect on TRL apoB-48 and VLDL apoB-100 levels or kinetics.
authors.affiliation: Institute of Nutrition and Functional Foods, Laval University, Quebec City, QC, Canada G1V 0A6.
authors.forename: André J
authors.initials: AJ
authors.lastname: Tremblay
authors.affiliation: Institute of Nutrition and Functional Foods, Laval University, Quebec City, QC, Canada G1V 0A6.
authors.forename: Benoît
authors.initials: B
authors.lastname: Lamarche
authors.affiliation: Institute of Nutrition and Functional Foods, Laval University, Quebec City, QC, Canada G1V 0A6.
authors.forename: Jean-Charles
authors.initials: JC
authors.lastname: Hogue
authors.affiliation: Institute of Nutrition and Functional Foods, Laval University, Quebec City, QC, Canada G1V 0A6; CHUQ Research Center, Laval University, Quebec City, QC, Canada G1V 4G2.
authors.forename: Patrick
authors.identifier: 0000-0002-8414-3847
authors.initials: P
authors.lastname: Couture
mesh_terms: D053299:Apolipoprotein B-100 / Q000097:blood*; D053283:Apolipoprotein B-48 / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D018592:Cross-Over Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications* / Q000175:diagnosis; D019587:Dietary Supplements; D004281:Docosahexaenoic Acids / Q000008:administration & dosage*; D004311:Double-Blind Method; D050171:Dyslipidemias / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D015118:Eicosapentaenoic Acid / Q000008:administration & dosage*; D006801:Humans; D007700:Kinetics; D008079:Lipoproteins, VLDL / Q000097:blood*; D008297:Male; D008875:Middle Aged; D019518:Postprandial Period; D011792:Quebec; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood*
chemical_list: D053299:Apolipoprotein B-100; D053283:Apolipoprotein B-48; D015415:Biomarkers; D008079:Lipoproteins, VLDL; D014280:Triglycerides; C030106:very low density lipoprotein triglyceride; D004281:Docosahexaenoic Acids; D015118:Eicosapentaenoic Acid